Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

RNAi drug specialist ADARx raises $446M IPO

Summary by biopharmadive.com
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

2 Articles

The Manila TimesThe Manila Times
Lean Right

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics,...

·Manila, Philippines (the)
Read Full Article
biopharmadive.combiopharmadive.com
Center

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Thursday, September 24, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Initial Public Offering (IPO) icon

Initial Public Offering (IPO)

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal